Blog

DUBLIN – (BUSINESS WIRE) – The report “Hepatitis C – Competitive Landscape in 2021” has been added ResearchAndMarkets.com to offer.

Hepatitis C – Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with internal analyst know-how to enable a competitive assessment of the disease market.

In hepatitis C, the non-structural proteins 5A (NS5A) and 5B (NS5B) are major targets of drug developers. There are 138 drugs in the pipeline, 90% of which are molecules in the early stages of development. Large Pharma dominates research and development in this indication, with Gilead Sciences leading the way. The increased use of newer direct-acting antiviral therapies (DAAs) is expected to fuel the market, but a steady decline in the overall patient pool and high cost of newer DAAs are likely to limit market growth.

This report provides a data-driven overview of the current and future competitive landscape in hepatitis C therapeutics.

scope

Components of the report are:

• Disease epidemiology

• Evaluation of marketed drugs

• Pipeline drug evaluation

• Evaluation of clinical studies

• Commercial evaluation

• Social media overview

• Digital Marketing Overview

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies by reviewing pipeline products and technologies and identifying the companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the global Hepatitis C market.

• Increase sales by understanding key trends, innovative products and technologies, market segments, and companies that are expected to impact the global Hepatitis C Market in the future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of different competitors.

• Identify emerging players with potentially strong product portfolios and develop effective counter-strategies to gain a competitive advantage.

• Organize your sales and marketing activities by identifying the market categories and segments that offer maximum opportunities for consolidation, investment and strategic partnerships.

Key topics covered:

1 Introduction

1.1 Table of contents

1.2 Abbreviations

1.3 Associated reports

1.4 Upcoming Related Reports

2 summary

2.1 Main results

2.2 Key Events

3 Introduction

3.1 Scope of the report

3.2 Disease overview Epidemiology overview

3.3 epidemiology

4 Evaluation of marketed drugs

4.1 Overview of marketed drugs

4.2 Profiles of marketed drugs

5 pipeline assessment

5.1 Pipeline overview

5.2 Breakdown of the pipeline by region

5.3 Breakdown of the pipeline by molecule type and destination

5.4 Designations for drug evaluation

5.5 Success rates of the phase transition

5.6 Likelihood of approval

6 Evaluation of clinical studies

6.1 Overview of clinical studies by phase

6.2 Overview by region

6.4 Perspective of the therapeutic area

6.4 Main Sponsors

6.5 Registration Analysis

6.6 Feasibility study

7 Commercial Evaluation

7.1 Upcoming market catalysts

8 Social Media and Digital Marketing

8.1 Important Twitter chats

8.2 Top Brand Websites

8.3 Flow of trust and flow of citation

9 Appendix

Please visit https://www.researchandmarkets.com/r/auc2pi for more information on this report